The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback